Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 11/20 | 0.45 |
| ▸ | RAB9A | P51151 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184457 | 0.89 | MAPT (0.40) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL6764645 | 0.86 | MAPT (0.44) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL7248460 | 0.86 | MAPT (0.44) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL4858870 | 0.82 | NPC1 (0.60) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL4876970 | 0.77 | ALOX15 (0.55) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL2237588 | 0.76 | P2RX7 (0.62) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6179968 | 0.76 | MAPT (0.46) | MAPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL23389992 | 0.74 | P2RX7 (0.38) | NPC1P2RX7GRM5HTT | |
| SCHEMBL4065931 | 0.74 | HCAR3 (0.44) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL29796592 | 0.74 | P2RX7 (0.38) | NPC1P2RX7GRM5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120004889-A | ALK5 kinase inhibitor and preparation method and application thereof | 延边大学 | 2025-05-16 | — | — | CN | disclosed |
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | MAPT 4189/4885LMNA 3761/4885NPC1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.